New cancer therapies at international conference in Amsterdam

Amsterdam/Lugano, March 16, 2006 - The 4th International Symposium on Targeted Anticancer Therapies (TAT 2006), to be held in Amsterdam, The Netherlands, March 16-18, 2006, co-organized by the NDDO Research Foundation and the European Society for Medical Oncology (ESMO), provides updates on emerging new therapies for the treatment of cancer. Several new, so-called targeted anticancer agents are likely to be approved for use in daily practice in the near future. The ones that seem closest to obtaining marketing approval in the European Union are sorafenib (Nexavar) and sunitinib (Sutent). Both are being developed for kidney cancer (renal cell cancer) and have recently been approved by the US Food and Drug Administration. European marketing applications are under review by the European Medicines Agency (EMEA).

Sorafenib and sunitinib block specific target molecules that are important for tumor growth and development. They are considered real breakthroughs in the treatment of advanced kidney cancer, a disease that is difficult to treat with currently available drugs. No new drugs for kidney cancer have been introduced in the past ten years. At TAT 2006, sorafenib and sunitinib will be reviewed extensively, in particular by Professor Martin Gore of the Royal Marsden Hospital in London, who will present a keynote lecture on emerging treatments for kidney cancer during the Opening Ceremony on March 16.

Many targeted anticancer therapies, covering a wide variety of targets in tumor tissue or the tumor's environment, are the subject of extensive research and development activities worldwide. Many targeted agents are being tested in clinical trials and are showing promising results in patients with different types of cancers. Several targeted agents have already been approved for cancer therapy by regulatory agencies worldwide, including, but not limited to, bevacizumab (Avastin), cetuximab (Erbitux) and erlotinib (Tarceva). Updates on these agents and many

Contact: Dr. Marinus W. Lobbezoo
European Society for Medical Oncology

Page: 1 2

Related biology news :

1. Protein chatter linked to cancer activation
2. Newly created cancer stem cells could aid breast cancer research
3. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. No evidence that widely prescribed statins protect against prostate cancer
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. New study suggests Concord grape juice may provide protection against breast cancer
8. New test improves detection of liver cancer
9. High-intensity ultrasound may launch attack on cancer, wherever it lurks
10. Unknotting DNA clue to cancer syndrome
11. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer

Post Your Comments:

(Date:4/30/2020)... ... 2020 , ... Ever a responsive and supportive partner to ... critical information to life science organizations as they navigate the ever-changing economic and ... the most up-to-date actionable guidance and information has been a keystone of our ...
(Date:4/26/2020)... ... April 23, 2020 , ... ... miniaturization, backed by FII Tech Growth managed by Fondo Italiano d’Investimento SGR, today ... market, for the development of Respira, a new non-invasive pulmonary ventilator created in ...
(Date:4/22/2020)... WAYNE, Pa. (PRWEB) , ... April 20, 2020 , ... ... Sciences and Healthcare firms of all sizes, announces the hiring of Michael Wlodarczyk as ... Wlodarczyk has been tasked to support and grow the company’s already strong presence across ...
Breaking Biology News(10 mins):
(Date:5/5/2020)... ... 04, 2020 , ... Red Nucleus, a leading provider of ... that Informa Training Partners, a life sciences training company acquired by Red Nucleus ... immediately. , “The name change solidifies a stronger presence for Red Nucleus in ...
(Date:4/26/2020)... ... April 23, 2020 , ... ... today, an online store providing applications and services for use on Microsoft Azure. ... business needs to sign up online for a built-for-purpose customer engagement capability to ...
(Date:4/22/2020)... ... April 21, 2020 , ... ... through COVID-19. Many clinical trial teams are working remotely and have paused patient ... to help researchers continue their research during this uncertain time by giving research ...
(Date:4/1/2020)... ... 2020 , ... Kinetic Vet, an animal health company, today ... solution. As a first-of-its-kind technology within the animal health industry, ArmourGuard RTU ... up to 90 days. , In addition to reducing the cross contamination that ...
Breaking Biology Technology:
Cached News: